AI brief of an SEC Form 8-K · Solstice Advanced Materials (SOLS)

Solstice Q4 sales rise 8% to $987 million, but net income falls 69% to $41 million

Mixed Impact 3 of 5 earnings Written later

Solstice Advanced Materials reported fourth quarter 2025 net sales of $987 million, up 8% from a year earlier, but net income attributable to the company fell 69% to $41 million and Adjusted Standalone EBITDA fell 20% to $189 million. The company also issued 2026 guidance of $3.9 billion to $4.1 billion in net sales and $975 million to $1.025 billion in Adjusted EBITDA, and declared its first quarterly dividend of $0.075 per share.

Key points

  • Q4 2025 net sales were $987 million, up 8%; net income attributable to Solstice was $41 million, versus $133 million in Q4 2024.
  • Full-year 2025 net sales were $3.9 billion, up 3%; net income attributable to Solstice was $237 million, versus $594 million in 2024.
  • 2026 guidance: net sales of $3.9 billion to $4.1 billion, Adjusted EBITDA of $975 million to $1,025 million, and Adjusted Diluted EPS of $2.45 to $2.75.
  • Quarterly dividend of $0.075 per share: record date February 24, 2026; payment date March 10, 2026.

The filing

CompanySolstice Advanced Materials (SOLS)
Form8-K, current report
Filed with the SECFeb 11, 2026, 6:07 AM ET
Accession number0002064953-26-000003

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.